In November of last year, Colorado healthcare workers at Denver Health received doses of the live Ebola vaccine.
Hospital officials said the Regional Emerging Special Pathogen Treatment Center team became some of the first to receive Merck’s ‘ERVEBO’ Ebola jab, for “preventative measures in case of a future outbreak.”
Follow Jon Fleetwood on Instagram @realjonfleetwood / Twitter @JonMFleetwood
ERVEBO Ebola Vaccine’s ‘Shedding’ Problem
The U.S. Food and Drug Administration’s (FDA) package insert for ERVEBO states that the vaccine “shed[s]” onto others 31.7% of the time and for up to 20 days after vaccination.
This means that vaccinated individuals can spread the disease to those around them.
“Vaccine virus RNA has been detected in blood, saliva, urine, and fluid from skin vesicles of vaccinated individuals,” the insert reads. “In Study 6, 31.7% (19/60) of participants 12 months through 17 years of age enrolled in a substudy shed vaccine virus in saliva following vaccination.”
Screenshot from fda.gov taken January 16, 2024.
This shedding problem could explain why Africa’s 2016, 2018, 2020, 2021, and 2022 Ebola outbreaks occurred after vaccination campaigns were carried out in those areas.
Given the established record of Ebola outbreaks following earlier vaccination campaigns in the same regions, concerns are raised about a future outbreak in Colorado—situated in the central U.S.—spreading across the country and perhaps the world.
New Ebola Bat Lab Just Down the Road from Denver Health
Meanwhile, a new $12 million, U.S.-taxpayer-funded lab is being built in Fort Collins, Colorado, just 65 miles north of Denver Health, where healthcare workers received the Ebola vaccine “in case of a future outbreak.”
The lab will import bats from around the world and experiment on dangerous diseases, according to The Daily Mail.
Proposals for the 14,000 sqft facility indicate the lab could store and study some of the most deadly or transmissible pathogens on the planet, including Ebola, Nipah virus, and COVID-19.
The project is a collaboration between Dr. Anthony Fauci’s old department at the National Institutes of Health (NIH), Colorado State University (CSU), and EcoHealth Alliance (EHA).
EcoHealth is the controversial New York-based research group at the center of the COVID lab leak theory led by Dr. Peter Daszak, who channeled millions of American taxpayer dollars to fund risky gain-of-function research on bats at the Wahn Institute of Virology (WIV) in Wuhan, China.
The WIV laboratory is argued to be ground zero for the coronavirus pandemic.
Pushing Ebola Treatment Remdesivir, Which Has a 53% Mortality Rate
Amplifying these concerns, RedHill Biopharma Ltd., a specialty biopharmaceutical company headquartered in both Tel-Aviv, Israel and Raleigh, North Carolina, recently reported findings regarding its two new drugs for treating Ebola, Opaganib and RHB-107.
The development of the investigational drugs is funded by the U.S. Army.
The company claims its the two medicines ought to be combined with the nucleotide prodrug remdesivir (Veklury®).
However, while Ebola has a 50% death rate, those infected with Ebola die at a higher rate (“exceeded 50%”) after taking remdesivir, The New England Journal of Medicine (NEJM) confirmed, calling into question the drug’s efficacy.
Screenshot from NEJM.org taken January 16, 2024.
